| Literature DB >> 28730446 |
Angelica N Martins1, Weina Ke2, Vaishnavi Jawahar1,2, Morriah Striplin2, Caryn Striplin2, Eric O Freed3, Kirill A Afonin4,5,6.
Abstract
Human immunodeficiency virus Type 1 (HIV-1) is the major cause of acquired immune deficiency syndrome (AIDS). In 2014, it was estimated that 1.2 million people died from AIDS-related illnesses. RNA interference-based therapy to block HIV replication is a field that, as of now, is without any FDA-approved drugs available for clinical use. In this chapter we describe a protocol for testing and utilizing a new approach that relies on reassociation of RNA-DNA hybrids activating RNAi and blocking HIV replication in human cells.Entities:
Keywords: Dicer substrate RNA; HIV-1; Hybrids reassociation; RNA interference; RNA nanotechnology; RNA–DNA hybrids
Mesh：
Substances：
Year: 2017 PMID： 28730446 PMCID： PMC6941940 DOI： 10.1007/978-1-4939-7138-1_18
Source DB: PubMed Journal: Methods Mol Biol ISSN： 1064-3745